

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

宜明昂科生物醫藥技術（上海）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1541)

**ANNOUNCEMENT
INTERIM REPORT
FOR THE SIX MONTHS ENDED JUNE 30, 2023**

This announcement is made by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to the Note to Rule 13.48(1) of The Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The board of directors (the “**Board**”) of the Company wishes to inform all shareholders and potential investors of the Company that,

- i) the interim financial information of the Group prepared in accordance with International Accounting Standard 34 “Interim Financial Reporting” for the six months ended June 30, 2023;
- ii) a statement as to the Company’s compliance with the code provisions in Part 2 of Appendix 14 to the Listing Rules; and
- iii) a statement as to that the Company is not in breach of its articles of association, laws and regulations of the People’s Republic of China or other regulatory requirements regarding its obligation to publish and distribute its interim report in accordance with the requirements under Rule 13.48(1) of the Listing Rules,

were included in the prospectus of the Company dated August 24, 2023, which is available for viewing on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.immuneonco.com). As such, pursuant to the Note to Rule 13.48(1) of the Listing Rules, the Company will not separately publish an interim report or a summary interim report for the six months ended June 30, 2023 on the website of the Stock Exchange or the Company under Rule 13.48(1) of the Listing Rules.

By order of the Board
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
宜明昂科生物醫藥技術（上海）股份有限公司
Tian Wenzhi
Chairman and Executive Director

Hong Kong, September 26, 2023

As at the date of this announcement, the Board comprises (i) Dr. Tian Wenzhi, Mr. Li Song and Ms. Song Ziyi as executive directors; (ii) Dr. Xu Cong, Mr. Yu Zhihua and Mr. Yu Xiaoyong as non-executive directors; and (iii) Dr. Zhenping Zhu, Dr. Kendall Arthur Smith and Mr. Yeung Chi Tat as independent non-executive directors.